Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.32
Nov 20 • 3:59 PM ET Dollar change-0.13 Percentage change(-8.97%)
Aftermarket Close
1.34
Aftermarket • 5:47 PM ET Dollar change+0.02 Percentage change(1.52%)
Nov 19, 2:10 AMEvotec said its Bristol Myers Squibb protein-degradation partnership received FDA acceptance for a second investigational drug candidate.
Index
-
Market Cap
468.84M
Enterprise Value
560.71M
Income
-210.64M
Sales
834.63M
Book/sh
2.05
Cash/sh
1.28
Employees
4553
IPO
Feb 05, 2004
P/E
-
Forward P/E
-
PEG
-
P/S
0.56
P/B
0.64
P/C
1.03
P/FCF
-
EV/EBITDA
-
EV/Sales
0.67
Quick Ratio
2.19
Current Ratio
2.32
Debt/Eq
0.75
LT Debt/Eq
0.65
Option/Short
No / Yes
EPS (ttm)
-0.59
EPS next Y
-0.24
EPS next Q
-0.13
EPS this Y
-135.75%
EPS next Y
69.82%
EPS next 5Y
76.90%
EPS past 3/5Y
14.30% -
Sales past 3/5Y
4.05% 9.27%
EPS Y/Y TTM
-19.37%
Sales Y/Y TTM
0.31%
EPS Q/Q
38.96%
Sales Q/Q
-0.93%
Insider Own
5.17%
Insider Trans
0.00%
Inst Own
0.55%
Inst Trans
-3.80%
ROA
-11.11%
ROE
-25.24%
ROIC
-17.51%
Gross Margin
13.23%
Oper. Margin
-15.41%
Profit Margin
-25.24%
SMA20
-16.30%
SMA50
-15.52%
SMA200
-44.25%
Trades
Shs Outstand
355.18M
Shs Float
336.82M
52W High
3.87 -65.89%
52W Low
1.33 -0.75%
Volatility
3.43% 3.58%
ATR (14)
0.08
RSI (14)
32.17
Beta
1.97
Rel Volume
0.72
Avg Volume
108.19K
Volume
77,590
Perf Week
-16.46%
Perf Month
-14.29%
Perf Quarter
-30.16%
Perf Half Y
-56.44%
Perf YTD
-57.14%
Perf Year
-54.48%
Perf 3Y
-87.46%
Perf 5Y
-94.42%
Perf 10Y
-59.10%
Prev Close
1.45
Price
1.32
Change %
-8.97%
Consensus
Buy
Avg. Price Target
$2.52
Implied Upside
+90.9%
Analysts10incl. previous ratings
Rating Distribution4 Buy · 6 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 16, 2026Downgrade
BBerenberg
Buy → Hold
Jul 15, 2026Downgrade
TD logoTTD Cowen
Buy → Hold$2+51.5%
Apr 15, 2026Resumed
HH.C. Wainwright
Buy$7+430.3%
Feb 03, 2026Initiated
BBerenberg
Buy
Apr 24, 2025Upgrade
DB logoDDeutsche Bank
Sell → Hold
Oct 07, 2024Downgrade
JEF logoJJefferies
Buy → Hold
Aug 08, 2024Downgrade
DB logoDDeutsche Bank
Hold → Sell
Jul 29, 2024Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$15 → $6+354.5%
Jul 11, 2024Downgrade
DB logoDDeutsche Bank
Buy → Hold
Apr 12, 2024Upgrade
DB logoDDeutsche Bank
Hold → Buy
Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just-Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just-Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.
CEO & Chairperson of the Management BoardDr. Christian Wojczewski Ph.D.
Chief People Officer & Member of Management BoardMs. Aurelie Dalbiez
CFO & Member of Management BoardMs. Claire Hinshelwood
COO & Member of Management BoardDr. Ingrid Mller
Chief Scientific Officer & Member of the Management BoardDr. Joanna Holbrook